Abstract

Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn’s disease. It is a group of chronic disorders characterized by inflammation of the gastrointestinal track with unknown etiology. Currently applied biomarkers include CRP, ESR, pANCA, ASCA, and fecal calprotectin. The etiopathogenesis of IBD is multifactorial. In patients with IBD in inflamed alimentary tract mucosa the number of recruited monocytes and activated macrophages which are source of cytokines. In IBD, the exacerbation is accompanied by thrombocytosis. Platelets play a crucial role in the hemostasis and inflammatory response. Selectins, which regulates the hemostasis and inflammatory response, stimulates the secretion of many inflammatory mediators such as β-thromboglobuline, CD40L, fibrinogen, IL-1β, platelet factor-4. In the course of IBD the following changes are observed: an increase in the number of platelets (reactive thrombocytosis), PDW and PCT, reduction in MPV, increased production and excretion of granular content products (P-selectin, GP53, β-TG, PF-4, vWF, fibrinolytic inhibitors).

References

• 1. Ananthakrishnan A.N.: Epidemiology and risk factors for IBD.Nat. Rev. Gastroenterol. Hepatol., 2015; 12: 205-214
  Google Scholar
• 2. Andoh A., Tsujikawa T., Hata K., Araki Y., Kitoh K., Sasaki M.,Yoshida T., Fujiyama Y.: Elevated circulating platelet-derived microparticlesin patients with active inflammatory bowel disease. Am.J. Gastroenterol., 2005; 100 (9): 2042-2048
  Google Scholar
• 3. Andoh A., Yagi Y., Shioya M., Nishida A., Tsujikawa T., FujiyamaY.: Mucosal cytokine network in inflammatory bowel disease. WorldJ. Gastroenterol., 2008; 14 (33): 5154-5161
  Google Scholar
• 4. Bager P.: Anemia in inflammatory bowel diseases in much morethan levels of haemoglobin. J. Gastrointestin. Liver Dis., 2015; 2:145-146
  Google Scholar
• 5. Bargen J., Barker N.W.: Extensive arterial and venous thrombosiscomplicating chronic ulcerative colitis. Arch. Intern. Med.,1936; 58:17-31
  Google Scholar
• 6. Buderus S., Boone J.H., Lentze M.J.: Fecal lactoferrin: reliable biomarkerfor intestinal inflammation in pediatric IBD. Gastroenterol.Res. Pract., 2015; 578527, 1-4
  Google Scholar
• 7. Cekic C., Arabul M., Alper E., Pakoz Z.B., Yuksel Saritas E., UnsalB.: Evaluation of the relationship between serum ghrelin, C-reactiveprotein and interleukin-6 levels, and disease activity in inflammatorybowel diseases. Hepatogastroenterology, 2014; 61 (133): 1196-1200
  Google Scholar
• 8. Cioffi M., de Rosa A., Serao R., Picone I., Vietri M.T.: Laboratorymarkers in ulcerative colitis: current insights and future advances.World J. Gastrointest. Pathophysiol., 2015; 6 (1): 13-22
  Google Scholar
• 9. Cromer W.E., Mathis J.M., Granger D.N., Chaitanya G.V., AlexanderJ.S.: Role of the endothelium in inflammatory bowel diseases. WorldJ. Gastroenterol., 2011; 17 (5): 578-593
  Google Scholar
• 10. Dolapcioglu C., Soylu A., Kendir T., Tuzun Ince A., DolapciogluH., Purisa S., Bolukbas C. Mehmet Sokmen H., Dalay R., Ovunc O.:Coagulation parameters in inflammatory bowel disease. Int. J. Clin.Exp. Med., 2014; 7(5):1442-1448
  Google Scholar
• 11. Fakhoury M., Negrulj R., Mooranian A., Al-Salami H.: Inflammatorybowel disease: clinical aspects and treaments. J. InflammationReasearch, 2014; 7:113-120
  Google Scholar
• 12. Fengming Y., Jianbing W.: Biomarkers of inflammatory boweldisease. Dis. Markers, 2014; ID:710915: 1-11
  Google Scholar
• 13. Korolkova O.Y., Myers J.N., Pellom S.T., Wang L., M’Koma A.E.:Characterization of serum cytokine profile in predominantly colonicinflammatory bowel disease to delineate ulcerative and Crohn’scolitides. Clin. Med. Insights Gastroenterol., 2015; 8:29-44
  Google Scholar
• 14. Liu S., Ren J., Han G., Wang G., Gu G., Xia Q., Li J.: Mean plateletvolume: a controversial marker of disease activity in Crohn’s disease.Eur. J. Med. Research, 2012; 17: 27, 1-7
  Google Scholar
• 15. Magro F., Araujo F., Pereira P., Meireles E., Diniz-Ribeiro M., VelosomF.T.: Soluble selectins, sICAM, sVCAM, and angiogenic proteinsin different activity groups of patients with inflammatory boweldisease. Dig. Dis. Sci., 2004; 49, (7-8): 1265-1274 16 Magro F., Soares J.-B., Fernandes D.: Venous thrombosis andprothrombotic factors in inflammatory bowel disease. World J. Gastroenterol.,2014; 20 (17): 4857-4872
  Google Scholar
• 16. (3): 118-124
  Google Scholar
• 17. Matowicka-Karna J., Kamocki Z., Kemona H.: Assessment of plateletactivation and phagocytic activity in gastric cancer patients.World J. Gastrointest. Pathophysiol., 2013; 4 (1) :12-17
  Google Scholar
• 18. Menees S.B., Powell C., Kurlander J., Goel A., Chey W.D.: A meta–analysis of utility of C-reactive protein, erythrocyte sedimentationrate, fecal calprotectin, and fecal lactoferrin to exclude inflammatorybowel disease in adults with IBS. Am. J. Gastroenterol., 2015;110:444-454
  Google Scholar
• 19. Morowitz D.A., Allen L.W., Kirsner J.B.: Thrombocytosis in chronicinflammatory bowel disease. Ann. Intern. Med., 1968; 68: 1013-1021
  Google Scholar
• 20. Mosli M.H., Zou G., Garg S.K., Faegan S.G., MacDonald J.K., ChandeN., Sandborn W.J., Feagan B.G.: C-reactive protein, fecal calprotectin,and stool lactoferrin for detection of endoscopic activity insymptomatic inflammatory bowel disease patients: a systematic reviewand meta-analysis. Am. J. Gastroenterol., 2015; 110 (6): 802-819
  Google Scholar
• 21. Mouelhi L., Mekki H., Debbeche R., Salem M., Najjar T.: Thrombosisin inflammatory bowel disease: mechanisms and risk factors.Tunis. Med. 2009; 87 (5): 307-310
  Google Scholar
• 22. Owczarek D., Cibor D., Głowacki M.K., Rodacki T., Mach T.: Inflammatorybowel disease: epidemiology, pathology and risk factorsfor hypercoagulability. World J. Gastroenterol., 2014; 20(1): 53-63
  Google Scholar
• 23. Ozturk Z.A., Dag M.S., Kuyumcu M.E., Cam H., Yesil Y., YilmazN., Aydinli M., Kadayifci A., Kepekci Y.: Could platelet indices be newbiomarkers for inflammatory bowel diseases? Eur. Rev. Med. Pharmacol.Sci., 2013; 17: 334-341
  Google Scholar
• 24. Palkovits J., Novacek G., Kollars M., Hron G., Osterode W., QuehenbergerP., Kyrle P.A., Vogelsang H., Reinisch W., Papay P., WeltermannA.: Tissue factor exposing microparticles in inflammatorybowel disease. J. Crohns Colitis, 2013; 7 (3): 222-229
  Google Scholar
• 25. Polinska B., Matowicka-Karna J., Kemona H.: Assessment of theinfluence of the inflammatory process on the activation of blood plateletsand morphological parameters in patients with ulcerative colitis(colitis ulcerosa). Folia Histochem. Cytobiol., 2011; 49 (1): 119-124
  Google Scholar
• 26. Ripoche J.: Blood platelets and inflammation: their relationshipwith liver and digestive diseases. Clin. Res. Hepatol. Gastroenterol.,2011; 35: 353-357
  Google Scholar
• 27. Saluk J., Bijak M., Ponczek M., Wachowicz B.: The formation,metabolism and the evolution of blood platelets. Postepy Hig. Med.Dosw., 2014; 68: 384-391
  Google Scholar
• 28. Scaldaferii F., Lancellotti S., Pizzoferrato M., De Cristofaro R.:Haemostatic system in inflammatory bowel diseases: new playersin gut inflammation. World J. Gastroenterol., 2011; 17(5): 594-608
  Google Scholar
• 29. Sipeki N., Davida L., Palyu E., Altorjay I., Harsfalvi J., Antal SzalmasP., Szabo Z., Veres G., Shums Z., Norman G.L., Lakatos P.L., Papp M.: Prevalence,significance and predictive value of antiphospholipid antibodiesin Crohn’s disease. World J. Gastroenterol., 2015; 21(22): 6952-6964
  Google Scholar
• 30. Stadnicki A.: Involvement of coagulation and hemostasis ininflammatory bowel diseases. Curr. Vasc. Pharmacol., 2012; 10 (5):659-669
  Google Scholar
• 31. Tang J., Gao X., Zhi M., Zhou H.M., Zhang M., Chen H.W., YangQ.F., Liang Z.Z.: Plateletcrit: a sensitive biomarker for evaluatingdisease activity in Crohn’s disease with hs-CRP. J. Dig. Dis., 2015;
  Google Scholar
• 32. Tekelioglu Y., Uzun H., Sisman G.: Activated platelets in patientssuffering from inflammatory bowel disease. Bratisl. Lek. Listy, 2014; 115 (2): 83-85
  Google Scholar
• 33. Toptygina A.P., Semikina E.L., Bobyleva G.V., Miroshkina L.V.,Petrichuk S.V.: Cytokine profile in children with inflammatory boweldisease. Biochemistry (Mosc.), 2014; 79, 12: 1371-1375
  Google Scholar
• 34. Vatn M.H., Sandvik A.K.: Inflammatory bowel disease. Scand. J.Gastroenterol., 2015; 50: 748-762
  Google Scholar
• 35. Voudoukis E., Karmiris K., Koutroubakis I.E.: Multipotent role ofplatelets in inflammatory bowel diseases: a clinical approach. WorldJ. Gastroenterol., 2014; 20 (12): 3180-3190
  Google Scholar
• 36. Wilson A., Teft W.A., Morse B.M., Choi Y.H., Woolsey S., DeGorterM.K., Hegele R.A., Tirona R.G., Kim R.B.: Trimethylamine–N-oxide:a novel biomarker for the identification of inflammatory bowel disease.Dig. Dis. Sci., 2015; PMID: 26160437
  Google Scholar
• 37. Wu P., Xie F., Xue M., Xu X., He S., Lin M.: Advanced oxidationprotein products decrease the expression of calcium transport channelsin small intestinal epithelium via the p44/42 MAPK signalingpathway. Eur. J. Cell Biol.,
  Google Scholar
• 38. Xie F., Sun S., Xu A., Zheng S., Xue M., Wu P., Zeng J.H., Bai L.: Advancedoxidation protein products induce intestine epithelial cell deaththrough a redox-dependent, c-jun N-terminal kinase and poly (ADP-ribose)polymerase-1-mediated pathway. Cell Death Dis., 2014, 5 (1): e1006
  Google Scholar
• 39. Yoshida H., Granger D.N.: Inflammatory bowel disease: a paradigmfor the link between coagulation and inflammation. Inflamm.Bowel Dis., 2009; 15 (8): 1245-1255
  Google Scholar
• 40. Yuksel O., Helvaci K., Basar O., Koklu S., Caner S., Helvaci N.,Abayli E., Altiparmak E.: An overlooked indicator of disease activityin ulcerative colitis mean platelet volume. Platelets, 2009; 20: 277-281
  Google Scholar
• 41. Zanoli L., Inserra G., Castellino P.: Increased cardiovascular riskin subjects with a low prevalence of classic cardiovascular risk factor:the inflammatory bowel disease paradox. Trends Cardiovasc. Med.,2015; dx.doi.org/10.1016/j.tcm.2015.04.001
  Google Scholar
• 42. Zatorski H., Sałaga M., Zielińska M., Fichna J.: Genetic factors inpathogenesis, course and treatment of inflammatory bowel diseases.Post. Hig. Med. Dośw., 2015; 69: 335-344
  Google Scholar
• 43. Zezos P., Kouklakis G., Saibil F.: Inflammatory bowel disease andthromboembolism. World J. Gastroenterol., 2014; 20 (38):13863-13878
  Google Scholar

Full text